This is an application for a five-year competitive renewal for years 21-26 of the present NCI-Designated Mayo Comprehensive Cancer Center. Over the past four years, the Mayo Foundation has made a major investment in cancer research with construction of new laboratory space, recruitment of more than 25 basic scientists. and the creation of 9 basic science cores available to all investigators at the Institution. The expansion in basic science has led to the development of four new basic science programs in the Cancer Center: Cancer Genetics, Growth Factors, Cell Signalling, and Gene Regulation. These programs include the 25 investigators previously-participating in the former """"""""Immunology"""""""" and """"""""Biochemistry and Molecular Biology"""""""" programs as well as 30 new investigators. The programs in Clinical Trials and Cancer Pharmacology have also been strengthened by the addition of new personnel. In the current application, support is requested for nine cores: 1) Admini- stration, 2) Statistical and Clinical Research Support Systems, 3) Pharmacy, 4) Pathology, 5) Cellular Immunology , 6) Pharmacology, 7) Cytogenetics, 8) Molecular Probes, and 9) Peptide Synthesis and Sequencing. The Peptide Synthesis and Sequencing core is new. A capability for histologic preparation has been added to the Pathology Core (formerly """"""""Tissue Distribution""""""""). Increased developmental funds are requested to support a broadly based developing cancer control and prevention program, a developing program in radiation oncology, a state- of-the-art confocal microscopy/subcellular manipulation core, and an epidemiology core to support future programs in control and the new program in cancer genetics. Total direct costs requested in year 1 are $1.86 million.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-20
Application #
3101458
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1988-03-01
Project End
1997-02-28
Budget Start
1993-04-07
Budget End
1994-02-28
Support Year
20
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1129 publications